title: Correlation of microvessel density with nuclear pleomorphism, mitotic count and vascular invasion in breast and prostate cancers at preclinical and clinical levels.
abstract: BACKGROUND
  Tumor angiogenesis correlates with recurrence and appears to be a prognostic factor for both breast and prostate cancers. In the present study, we aimed to investigate the correlation of microvessel density (MVD), a measure of angiogenesis, with nuclear pleomorphism, mitotic count, and vascular invasion in breast and prostate cancers at preclinical and clinical levels.
  
  
  METHODS
  Samples from xenograft tumors of luminal B breast cancer and prostate adenocarcinoma, established by BT-474 and PC-3 cell lines, respectively, and commensurate human paraffin-embedded blocks were obtained. To determine MVD, specimens were immunostained for CD-34. Nuclear pleomorphism, mitotic count, and vascular invasion were determined using hematoxylin and eosin (HandE)-stained slides.
  
  
  RESULTS
  MVD showed significant correlations with nuclear pleomorphism (r=0.68, P=0.03) and vascular invasion (r=0.77, P=0.009) in breast cancer. In prostate cancer, MVD was significantly correlated with nuclear pleomorphism (r=0.75, P=0.013) and mitotic count (r=0.75, P=0.012). In the breast cancer xenograft model, a significant correlation was observed between MVD and vascular invasion (r=0.87, P=0.011). In the prostate cancer xenograft model, MVD was significantly correlated with all three parameters (nuclear pleomorphism, r=0.95, P=0.001; mitotic count, r=0.91, P=0.001; and vascular invasion, r=0.79, P=0.017; respectively).
  
  
  CONCLUSIONS
  Our results demonstrate that MVD is correlated with nuclear pleomorphism, mitotic count, and vascular invasion at both preclinical and clinical levels. This study therefore supports the predictive value of MVD in breast and prostate cancers.
authors.affiliation: Cancer Research Centre, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Samad
authors.initials: S
authors.lastname: Muhammadnejad
authors.forename: Ahad
authors.initials: A
authors.lastname: Muhammadnejad
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Haddadi
authors.forename: Mohammad-Ali
authors.initials: MA
authors.lastname: Oghabian
authors.forename: Mohammad-Ali
authors.initials: MA
authors.lastname: Mohagheghi
authors.forename: Farrokh
authors.initials: F
authors.lastname: Tirgari
authors.forename: Fariba
authors.initials: F
authors.lastname: Sadeghi-Fazel
authors.forename: Saeid
authors.initials: S
authors.lastname: Amanpour
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008297:Male; D055806:Microvessels / Q000473:pathology*; D008940:Mitotic Index; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009374:Neoplasms, Experimental; D011471:Prostatic Neoplasms / Q000473:pathology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen